Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q3 2020 · 10-Q
Revenue$136.00K$136.00K+163.1% vs Q3 2019 Net Income-$4.50M-$4.50MN/M vs Q3 2019 EPS Diluted-$0.19-$0.19N/M vs Q3 2019 Operating Income-$4,363,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$3,680,000N/M Margins · derivedOperating margin-3208.1%+4932.2 pt vs Q3 2019
Net margin-3306.6%+4706.1 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 5, 2020 · 36 d after period end